Survival Impact of Immediate Complete Lymph Node Dissection for Chinese Acral and Cutaneous Melanoma with Micrometastasis in Sentinel Nodes: A Retrospective Study

Author:

Zhong Jingqin1,Zou Zijian1,Hu Tu1,Sun Wei1,Wang Chunmeng1,Yan Wangjun1,Luo Zhiguo2,Liu Xin2,Xu Yu1,Chen Yong1

Affiliation:

1. Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center

2. Department of Medical Oncology, Fudan University Shanghai Cancer Center

Abstract

Abstract Background Sentinel node biopsy (SNB) has become a critical part of standard surgical treatment for melanoma with no metastatic evidence. According to MSLT-II and DeCOG-SLT trials, for patients with positive sentinel nodes, immediate complete lymph node dissection (CLND) didn’t bring further benefit for patients’ survival. Argument remains among Chinese population with domination of acral subtypes whether CLND can be omitted. This study aims to investigate the impact of immediate CLND for SN positivity on relapse-free survival (RFS) in Chinese melanoma patients.Material and Methods Patients with acral or cutaneous melanoma of clinical stage I-II receiving SNB procedure and then detected with nodal micrometastasis were retrospectively identified at Fudan University Cancer Center (FUSCC) from January 2017 to December 2021. Clinicopathologic features and prognostic factors for RFS were analyzed.Results Among 381 patients who received SNB in the last five years, 130 (34%) cases with positive SN micrometastasis detected were identified in our study. 99 patients underwent immediate CLND while the other patients received observation alone. Among patients received CLND, the NSN positive rate was 22.2%. There were slightly less N1 stage in the CLND group compared to the non-CLND group, although the difference didn’t reach statistical significance (P = 0.075). There was no significant difference in RFS between the two groups (P = 0.184).Conclusions Immediate CLND didn’t bring further RFS benefit after an observation for Chinese melanoma with SN micrometastasis in real clinical practice, even for patients with acral subtype or more tumor burden such as thick Breslow invasion and ulceration.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3